Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...
The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...
Patritumab deruxtecan (HER3-DXd), a HER3 directed ADC, ifinatamab deruxtecan (I-DXd), a B7-H3 directed ADC, and raludotatug deruxtecan (R-DXd), a CDH6 directed ADC, are being jointly developed and ...
Patritumab deruxtecan (HER3-DXd), a HER3 directed ADC, ifinatamab deruxtecan (I-DXd), a B7-H3 directed ADC, and raludotatug deruxtecan (R-DXd), a CDH6 directed ADC, are being jointly developed and ...
MedPage Today on MSN13d
Taking on Acquired Resistance in EGFR-Mutant NSCLCThe antibody-drug conjugate (ADC) patritumab deruxtecan (HER3-DXd) is a promising treatment for EGFR inhibitor-resistant ...
and Daiichi Sankyo is attempting to gain approval for its ADC patritumab deruxtecan. AstraZeneca, which also has a cancer drug partnership with Daiichi, markets Imfinzi and Tagrisso for several ...
Patritumab deruxtecan starts phase 3 Daiichi Sankyo meanwhile has started a phase 3 trial of another ADC – patritumab deruxtecan – comparing the drug to chemotherapy as a second-line therapy ...
Patritumab deruxtecan, which is currently leading the anti-HER3 pipeline, has shown efficacy in heavily pre-treated patients with EGFR-mutated NSCLC previously treated with multiple EGFR ...
and patritumab deruxtecan - have delivered promising data in lung cancer). There is also a promising late-stage RSV vaccine candidate, cardiovascular drug MK5475, and four immunology drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback